Raymond James Financial
DWTX

Raymond James Financial’s Dogwood Therapeutics DWTX Stock Holding History

Raymond James Financial’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24
Closed -$114 – 6940
2025
Q2 		$114 Buy
+24
New +$116 ﹤0.01% 6833

Other funds holding DWTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Raymond James Financial's DWTX Position: Q3 2025 in Review

Raymond James Financial sold out of Dogwood Therapeutics (DWTX) in Q3 2025, closing a stake of 24 shares — an estimated $114 sold.

Raymond James Financial first reported a position in DWTX in Q2 2025 and held it in 1 quarter. The position peaked at $114 in Q2 2025. 12 funds tracked by Wall St. Rank hold DWTX as of Q3 2025.

  • Raymond James Financial reported no remaining Dogwood Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 24 Dogwood Therapeutics shares in Q3 2025, an estimated $114.
  • Raymond James Financial first reported a position in Dogwood Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Dogwood Therapeutics position peaked at $114 in Q2 2025.
  • 12 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.